Clinical results of glecirasib in combination with JAB-3312 (sitneprotafib) in KRAS G12C–mutated NSCLC published in The Lancet Respiratory Medicine
Andrea Wang-Gillam, M.D., Ph.D., Co-CEO, CMO and Global Head of R&D of Jacobio Pharma, stated: “Since glecirasib received approval in China this May for second-line NSCLC, we have continued to advance its development in the first-line setting. The all-oral combination of KRAS G12C and SHP2 inhibitors has the potential to bring new therapeutic options for patients in China.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.